Loading
A phase 1 trial of zoldonrasib (RMC-9805) alone or with daraxonrasib (RMC-6236) in KRAS G12D-mutant solid tumours, including pancreatic, bowel and non-small-cell lung cancer, run by Revolution Medicines, now recruiting.
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors is a phase 1/1b interventional study registered as NCT06040541 by Revolution Medicines, Inc., with an estimated 604 participants across the whole study. Two arms are recorded: RMC-9805 (zoldonrasib) monotherapy and RMC-9805 plus RMC-6236 (daraxonrasib). Conditions listed: non-small cell lung cancer, colorectal cancer, pancreatic ductal adenocarcinoma and advanced solid tumours. The registry carries no results; the combination cohort figures reported by the sponsor at ESMO GI 2026 sit on the pairing record g12d-plus-pan-ras.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares KRAS, Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.